I want to be cautiously optimistic on the recent performance of biotechs. Yesterday ending up being a decent day and today started off okay. The sector is not burning it up with outperformance but seems to taking a pause in the selling. I have been warning that this is a busy week and it continues […]
October 23-EOD
Not a lot of news in terms of data, although we saw BMY, AMGN, and LLY report earnings. The biotech sector was not as much of a relative underperformer today. Of course, it was still red and weak but today it was red and weak in the context of a broader market selloff. Volumes seemed […]
October 22-EOD
This is going to be another early and quick note as I have another afternoon of meetings. Biotechs, in general, continue to underperform and I suspect there is still more downside but some individual stocks are getting interesting. It looks like small and mid caps are most challenged. Once the large cap space finds a […]
October 18-EOD
It is a little early but the week seems to be winding down (as with most biotechs going down), so I am sending this out a little sooner than usual. Got some continuation news from the two bigger news story of the past week. There were some other events but did not generate nearly the […]
October 17- EOD
A mixed day in the market which was nice to see a day in which not all stocks were moving in the same direction. Obviously had some stock specific news with AMRN and the PSDV PDUFA and some more general biotech news. 1. AMRN was the stock of the day with about a 67% haircut […]
October 16- EOD
With the approach of an end (as temporary as it is likely to be) of the stalemate in Washington you thought we would be approaching the end of the macro driven market. While I think that is likely true, we still are going to have a knee jerk relief rally before it settles back down […]
October 15- EOD
While this may surprise you (not) but it was another macro driven day (I know you are probably getting as tired of reading that as I am of writing it). Volume also seems to be drying up as investor simply sit on their hands and wait for Washington to get off of their hands. Despite […]
October 14- EOD
It was another macro day and will be until the mess in Washington is cleared (to a certain extent) but even when that happens will we likely still be in a macro world but with a tail wind instead of a head wind. That being said, the sector seemed to ne relatively heavy today even […]
October 11- Morning note
Well, we have three straight days of interesting news with ECYT rounding out the week. I want to focus on that today and get this out earlier than usual as this could be actionable today. 1. Before diving into ECYT, GS was out with a report on PCYC where they raised their price target to […]
October 10-EOD
Macro, macro, macro but now it is to the other way. We did have another big piece of news hit last night in terms of CLL, which I will talk about for today’s note. 1. The news of the day (or actually last night) was the halting of the GILD idelalisib trial of previously treated […]
October 8- Mid Day
While I wanted some more news from the biotech sector this was not exactly what I was planning. I discuss my thoughts on ARIA in an article on the street, so I will not belabor it more here. There are a couple of broader points that I think are interesting in light on today’s action. […]
October 8- EOD
I would like to argue that it was more of the same today given the macro focus and that is likely true but today was certainly more of the same to an extreme extent. There are a couple of interesting bits of information but nothing that is altering the fundamentals of a stock or sector. […]
October 7- EOD
Macro, macro, and more macro. That seems to be driving the market and without any significant biotech specific news that was the word of the day. As we get closer to the debt ceiling the greater the headwind and the closer correlation between stock movements will get to 1. Biotechs will be particularly vulnerable given […]
October 4- EOD
It green morning with biotechs taking part in the early rally and showing perhaps some minor strength but nothing earth shattering. Again it was a relatively quiet day on the news front, so I will do a couple of quick hitters today. 1. PCYC got another positive sell side report. I think we are clearly […]
October 3- EOD
Outside of a weak day in the macro which appears mainly related to macro issues, there does not seem to be a ton of news. Biotechs were obviously weak with the broader market but there was some green sprinkled in but they were few and far between. I will highlight a couple of companies but […]
October 2- EOD
Some macro weakness today but biotechs seemed to hold up fairly well. While most were red, it did not seem to be overdone to the downside. Plus, there were some pockets of green. All in all, not a great day to be in biotechs but it could have been worse given the broader market. The […]
October 1- EOD
It was a fairly busy day today in biotech land the sentiment certainly appears more positive. They participated in the market rally even though most were not big losers in the recent macro selling. This is certainly positive going forward. I want to focus on the MRK news as it touches on a lot of […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
September 30-EOD
There was certainly some interesting news and action today. The market was weak early but biotech was much more mixed than one would have expected. It is good to see those pockets of strength during the broad market sell offs. 1. ARIA was interesting on two levels: AP113 data and Iclusig sales. There was additional […]
